Completed × Carcinoma, Ovarian Epithelial × Docetaxel × Clear all OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Phase 1 Completed
40 enrolled
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Phase 2 Completed
30 enrolled 7 charts
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
Phase 1 Completed
40 enrolled
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 1/2 Completed
58 enrolled 16 charts
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Phase 1 Completed
18 enrolled
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Completed
129 enrolled 17 charts
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
33 enrolled
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Phase 3 Completed
308 enrolled
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
Phase 3 Completed
1,050 enrolled
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Chemotherapy in Treating Patients With Solid Tumors
Phase 1/2 Completed
57 enrolled
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
Phase 1 Completed
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Phase 2 Completed
30 enrolled
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Completed
30 enrolled
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Phase 2 Completed
31 enrolled
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Phase 1/2 Completed